Company Encyclopedia
View More
name
Invesco Pharmaceuticals ETF
PJP.US
News
View More

First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN

First Trust Advisors LP reduced its stake in Amgen Inc. by 3.8% in Q2, selling 21,347 shares. Amgen's stock opened at $340.16, with a market cap of $183.17 billion. The company reported Q3 earnings of $5.64 per share, beating estimates, and announced a quarterly dividend of $2.38. Insiders sold shares, including EVP Murdo Gordon and SVP Rachna Khosla.

Market Beat·
US
AMGN
-1.52%
Market Beat·
US
AMGN
-1.52%

AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

PR Newswire·
US
ABBV
-0.66%
PR Newswire·
US
ABBV
-0.66%

Glucose monitor problems linked with deaths, injuries: FDA

The FDA has linked at least seven deaths and hundreds of injuries to malfunctioning glucose monitors by Abbott Diabetes Care. The issue affects about 3 million FreeStyle Libre 3 and Libre 3 Plus devices, traced to one production line. Incorrect low glucose readings may lead to serious health risks. Abbott has reported 736 severe adverse events and is replacing affected sensors. The company has identified the issue's source and expects no major supply disruptions.

Thehill·
US
ABT
+0.09%
Thehill·
US
ABT
+0.09%

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener·
US
MRK
-1.35%
US
HALO
-2.64%
marketscreener·
US
MRK
-1.35%
US
HALO
-2.64%

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

Gilead Sciences Inc. (GILD) shares fell 1.90% to $122.62 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Gilead's stock is 4.72% below its 52-week high. Trading volume was 4.9M, below the 50-day average of 7.3M. Competitors' performances: Johnson & Johnson (JNJ) fell 1.39%, Pfizer Inc. (PFE) rose 0.51%, and Abbott Laboratories (ABT) rose 0.09%. Data source: Dow Jones Market Data, FactSet. Compiled December 4, 2025.

Dow Jones·
US
GILD
-1.90%
Dow Jones·
US
GILD
-1.90%
© 2025 Longbridge｜Disclaimer